{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:36:04Z","timestamp":1789058164476,"version":"build-2803163510"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Parasit."],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11686-021-00499-w","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:03:47Z","timestamp":1641859427000},"page":"582-591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["PLGA Nanoparticles as an Efficient Platform in Protein Vaccines Against Toxoplasma gondii"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7370-9315","authenticated-orcid":false,"given":"Mojgan","family":"Allahyari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"issue":"04","key":"499_CR1","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","volume":"363","author":"J Montoya","year":"2004","unstructured":"Montoya J, Liesenfeld O (2004) Toxoplasmosis. Lancet 363(04):1965\u20131976. https:\/\/doi.org\/10.1016\/S0140-6736(04)16412-X","journal-title":"Lancet"},{"issue":"11","key":"499_CR2","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.ijpara.2008.03.007","volume":"38","author":"JP Dubey","year":"2008","unstructured":"Dubey JP, Jones JL (2008) Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol 38(11):1257\u20131278. https:\/\/doi.org\/10.1016\/j.ijpara.2008.03.007","journal-title":"Int J Parasitol"},{"key":"499_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2325958219867315","volume":"18","author":"JE Vidal","year":"2019","unstructured":"Vidal JE (2019) HIV-related cerebral toxoplasmosis revisited: current concepts and controversies of an old disease. J Int Assoc Provid AIDS Care 18:1\u201320. https:\/\/doi.org\/10.1177\/2325958219867315","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"4","key":"499_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1086\/590149","volume":"47","author":"EJ Goldstein","year":"2008","unstructured":"Goldstein EJ, Montoya JG, Remington JS (2008) Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 47(4):554\u2013566. https:\/\/doi.org\/10.1086\/590149","journal-title":"Clin Infect Dis"},{"issue":"2","key":"499_CR5","doi-asserted-by":"publisher","first-page":"e01357","DOI":"10.1128\/JCM.01357-18","volume":"57","author":"TR Olariu","year":"2019","unstructured":"Olariu TR, Blackburn BG, Press C, Talucod J, Remington JS, Montoya JG (2019) Role of Toxoplasma IgA as part of a reference panel for the diagnosis of acute toxoplasmosis during pregnancy. J Clin Microbiol 57(2):e01357-e11318. https:\/\/doi.org\/10.1128\/JCM.01357-18","journal-title":"J Clin Microbiol"},{"issue":"2","key":"499_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/2229-5070.190813","volume":"6","author":"S Singh","year":"2016","unstructured":"Singh S (2016) Congenital toxoplasmosis: clinical features, outcomes, treatment, and prevention. Trop Parasitol 6(2):113\u2013122. https:\/\/doi.org\/10.4103\/2229-5070.190813","journal-title":"Trop Parasitol"},{"issue":"7","key":"499_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1586\/eri.12.58","volume":"10","author":"PA Moncada","year":"2012","unstructured":"Moncada PA, Montoya JG (2012) Toxoplasmosis in the fetus and newborn: an update on prevalence, diagnosis and treatment. Expert Rev Anti Infect Ther 10(7):815\u2013828. https:\/\/doi.org\/10.1586\/eri.12.58","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"499_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1128\/CMR.05013-11","volume":"25","author":"F Robert-Gangneux","year":"2012","unstructured":"Robert-Gangneux F, Darde ML (2012) Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev 25(2):264\u2013296. https:\/\/doi.org\/10.1128\/CMR.05013-11","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"499_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41541-017-0024-6","volume":"2","author":"K El Bissati","year":"2017","unstructured":"El Bissati K, Zhou Y, Paulillo SM, Raman SK, Karch CP, Roberts CW, Lanar DE, Reed S, Fox C, Carter D et al (2017) Protein nanovaccine confers robust immunity against Toxoplasma. NPJ Vaccines 2(1):24. https:\/\/doi.org\/10.1038\/s41541-017-0024-6","journal-title":"NPJ Vaccines"},{"issue":"12","key":"499_CR10","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1128\/AAC.02009-15","volume":"59","author":"AJ Neville","year":"2015","unstructured":"Neville AJ, Zach SJ, Wang X, Larson JJ, Judge AK, Davis LA, Vennerstrom JL, Davis PH (2015) Clinically available medicines demonstrating anti-toxoplasma activity. Antimicrob Agents Chemother 59(12):7161\u20137169. https:\/\/doi.org\/10.1128\/AAC.02009-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"499_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/VDT.S57474","volume":"4","author":"JL Garcia","year":"2014","unstructured":"Garcia JL, Innes EA, Katzer F (2014) Current progress toward vaccines against Toxoplasma gondii. Vaccine Devel Ther 4(4):23\u201337. https:\/\/doi.org\/10.2147\/VDT.S57474","journal-title":"Vaccine Devel Ther"},{"key":"499_CR12","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3389\/fmicb.2019.01875","volume":"10","author":"W-B Yang","year":"2019","unstructured":"Yang W-B, Wang J-L, Gui Q, Zou Y, Chen K, Liu Q, Liang Q-L, Zhu X-Q, Zhou D-H (2019) Immunization with a Live-attenuated RH: \u0394NPT1 strain of Toxoplasma gondii induces strong protective immunity against Toxoplasmosis in mice. Front Microbiol 10:1875. https:\/\/doi.org\/10.3389\/fmicb.2019.01875","journal-title":"Front Microbiol"},{"issue":"2","key":"499_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nri3598","volume":"14","author":"F Yarovinsky","year":"2014","unstructured":"Yarovinsky F (2014) Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol 14(2):109\u2013121. https:\/\/doi.org\/10.1038\/nri3598","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"499_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029955","volume":"7","author":"HM Fritz","year":"2012","unstructured":"Fritz HM, Bowyer PW, Bogyo M, Conrad PA, Boothroyd JC (2012) Proteomic analysis of fractionated toxoplasma oocysts reveals clues to their environmental resistance. PLoS ONE 7(1):e29955. https:\/\/doi.org\/10.1371\/journal.pone.0029955","journal-title":"PLoS ONE"},{"key":"499_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fcimb.2019.00046","volume":"9","author":"E Delgado Betancourt","year":"2019","unstructured":"Delgado Betancourt E, Hamid B, Fabian BT, Klotz C, Hartmann S, Seeber F (2019) From entry to early dissemination\u2014toxoplasma gondii\u2019s initial encounter with its host. Front Cell Infect Microbiol 9:46. https:\/\/doi.org\/10.3389\/fcimb.2019.00046","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"499_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/pathogens7030069","volume":"7","author":"LA Caldas","year":"2018","unstructured":"Caldas LA, de Souza W (2018) A window to Toxoplasma gondii egress. Pathogens 7(3):69. https:\/\/doi.org\/10.3390\/pathogens7030069","journal-title":"Pathogens"},{"issue":"12","key":"499_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008097","volume":"15","author":"D Fisch","year":"2019","unstructured":"Fisch D, Clough B, Frickel EM (2019) Human immunity to Toxoplasma gondii. PLoS Pathog 15(12):e1008097. https:\/\/doi.org\/10.1371\/journal.ppat.1008097","journal-title":"PLoS Pathog"},{"issue":"2","key":"499_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1590\/s0074-02762009000200019","volume":"104","author":"E Jongert","year":"2009","unstructured":"Jongert E, Roberts CW, Gargano N, Forster-Waldl E, Petersen E (2009) Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz 104(2):252\u2013266. https:\/\/doi.org\/10.1590\/s0074-02762009000200019","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"6","key":"499_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/bfgp\/elr028","volume":"10","author":"DR Weilhammer","year":"2011","unstructured":"Weilhammer DR, Rasley A (2011) Genetic approaches for understanding virulence in Toxoplasma gondii. Brief Funct Genomics 10(6):365\u2013373. https:\/\/doi.org\/10.1093\/bfgp\/elr028","journal-title":"Brief Funct Genomics"},{"issue":"1","key":"499_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mib.2006.06.017","volume":"10","author":"V Carruthers","year":"2007","unstructured":"Carruthers V, Boothroyd JC (2007) Pulling together: an integrated model of Toxoplasma cell invasion. Curr Opin Microbiol 10(1):83\u201389. https:\/\/doi.org\/10.1016\/j.mib.2006.06.017","journal-title":"Curr Opin Microbiol"},{"issue":"3","key":"499_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1017\/S0031182001008460","volume":"123","author":"F Velge-Roussel","year":"2001","unstructured":"Velge-Roussel F, Dimier-Poisson I, Buzoni-Gatel D, Bout D (2001) Anti-SAG1 peptide antibodies inhibit the penetration of Toxoplasma gondii tachyzoites into enterocyte cell lines. Parasitology 123(3):225\u2013233. https:\/\/doi.org\/10.1017\/S0031182001008460","journal-title":"Parasitology"},{"issue":"1","key":"499_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/1756-3305-7-180","volume":"7","author":"Y Wang","year":"2014","unstructured":"Wang Y, Yin H (2014) Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii. Parasit Vectors 7(1):180. https:\/\/doi.org\/10.1186\/1756-3305-7-180","journal-title":"Parasit Vectors"},{"key":"499_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2020.101414","volume":"69","author":"AS Pagheh","year":"2020","unstructured":"Pagheh AS, Sarvi S, Sharif M, Rezaei F, Ahmadpour E, Dodangeh S, Omidian Z, Hassannia H, Mehrzadi S, Daryani A (2020) Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: a systematic review. Comp Immunol Microbiol Infect Dis 69:101414. https:\/\/doi.org\/10.1016\/j.cimid.2020.101414","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"1","key":"499_CR24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/1471-2334-13-494","volume":"13","author":"M Meng","year":"2013","unstructured":"Meng M, Zhou A, Lu G, Wang L, Zhao G, Han Y, Zhou H, Cong H, Zhao Q, Zhu XQ et al (2013) DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB\/c mice. BMC Infect Dis 13(1):494. https:\/\/doi.org\/10.1186\/1471-2334-13-494","journal-title":"BMC Infect Dis"},{"key":"499_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fmicb.2016.00609","volume":"7","author":"XT Ching","year":"2016","unstructured":"Ching XT, Fong MY, Lau YL (2016) Evaluation of immunoprotection conferred by the subunit vaccines of GRA2 and GRA5 against acute toxoplasmosis in BALB\/c Mice. Front Microbiol 7:609. https:\/\/doi.org\/10.3389\/fmicb.2016.00609","journal-title":"Front Microbiol"},{"key":"499_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2019.105696","volume":"165","author":"F Rezaei","year":"2019","unstructured":"Rezaei F, Sharif M, Sarvi S, Hejazi SH, Aghayan S, Pagheh AS, Dodangeh S, Daryani A (2019) A systematic review on the role of GRA proteins of Toxoplasma gondii in host immunization. J Microbiol Methods 165:105696. https:\/\/doi.org\/10.1016\/j.mimet.2019.105696","journal-title":"J Microbiol Methods"},{"key":"499_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.exppara.2017.03.001","volume":"176","author":"Q Liu","year":"2017","unstructured":"Liu Q, Li FC, Zhou CX, Zhu XQ (2017) Research advances in interactions related to Toxoplasma gondii microneme proteins. Exp Parasitol 176:89\u201398. https:\/\/doi.org\/10.1016\/j.exppara.2017.03.001","journal-title":"Exp Parasitol"},{"issue":"1","key":"499_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00436-016-5298-5","volume":"116","author":"H Nabi","year":"2017","unstructured":"Nabi H, Rashid I, Ahmad N, Durrani A, Akbar H, Islam S, Bajwa AA, Shehzad W, Ashraf K, Imran N (2017) Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii. Parasitol Res 116(1):359\u2013370. https:\/\/doi.org\/10.1007\/s00436-016-5298-5","journal-title":"Parasitol Res"},{"key":"499_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2019.06.003","volume":"227","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Lai BS, Juhas M, Zhang Y (2019) Toxoplasma gondii secretory proteins and their role in invasion and pathogenesis. Microbiol Res 227:126293. https:\/\/doi.org\/10.1016\/j.micres.2019.06.003","journal-title":"Microbiol Res"},{"key":"499_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fcimb.2019.00103","volume":"9","author":"TS Lima","year":"2019","unstructured":"Lima TS, Lodoen MB (2019) Mechanisms of human innate immune evasion by Toxoplasma gondii. Front Cell Infect Microbiol 9:103. https:\/\/doi.org\/10.3389\/fcimb.2019.00103","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"499_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/intimm\/dxy004","volume":"30","author":"M Sasai","year":"2018","unstructured":"Sasai M, Pradipta A, Yamamoto M (2018) Host immune responses to Toxoplasma gondii. Int Immunol 30(3):113\u2013119. https:\/\/doi.org\/10.1093\/intimm\/dxy004","journal-title":"Int Immunol"},{"issue":"6","key":"499_CR32","doi-asserted-by":"publisher","first-page":"e00173","DOI":"10.1128\/IAI.00173-17","volume":"85","author":"SL Donahoe","year":"2017","unstructured":"Donahoe SL, Phalen DN, McAllan BM, O\u2019Meally D, McAllister MM, Ellis J, \u0160lapeta J (2017) Differential IFN-\u03b3 and TNF-\u03b1 driven cytokine response distinguishes acute infection of a metatherian host with Toxoplasma gondii and Neospora caninum. Infect Immun 85(6):e00173-e01117. https:\/\/doi.org\/10.1128\/IAI.00173-17","journal-title":"Infect Immun"},{"issue":"1","key":"499_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1073\/pnas.1011549108","volume":"108","author":"BD Hou","year":"2011","unstructured":"Hou BD, Benson A, Kuzmich L, DeFranco AL, Yarovinsky F (2011) Critical coordination of innate immune defense against Toxoplasma gondii by dendritic cells responding via their Toll-like receptors. PNAS USA 108(1):278\u2013283. https:\/\/doi.org\/10.1073\/pnas.1011549108","journal-title":"PNAS USA"},{"issue":"6","key":"499_CR34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/imt.11.68","volume":"3","author":"R Bhadra","year":"2011","unstructured":"Bhadra R, Gigley JP, Khan IA (2011) The CD8 T-cell road to immunotherapy of toxoplasmosis. Immunotherapy 3(6):789\u2013801. https:\/\/doi.org\/10.2217\/imt.11.68","journal-title":"Immunotherapy"},{"issue":"9","key":"499_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.pt.2011.03.009","volume":"27","author":"R Pifer","year":"2011","unstructured":"Pifer R, Yarovinsky F (2011) Innate responses to Toxoplasma gondii in mice and humans. Trends Parasitol 27(9):388\u2013393. https:\/\/doi.org\/10.1016\/j.pt.2011.03.009","journal-title":"Trends Parasitol"},{"issue":"5","key":"499_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126334","volume":"10","author":"A Wagner","year":"2015","unstructured":"Wagner A, Schabussova I, Ruttkowski B, Peschke R, Kur J, Kundi M, Joachim A, Wiedermann U (2015) Prime-boost vaccination with Toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB\/c mice. PLoS ONE 10(5):e0126334. https:\/\/doi.org\/10.1371\/journal.pone.0126334","journal-title":"PLoS ONE"},{"issue":"4851","key":"499_CR37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1126\/science.3128869","volume":"240","author":"Y Suzuki","year":"1988","unstructured":"Suzuki Y, Orellana MA, Schreiber RD, Remington JS (1988) Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 240(4851):516\u2013518. https:\/\/doi.org\/10.1126\/science.3128869","journal-title":"Science"},{"issue":"3","key":"499_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/14712598.2018.1413086","volume":"18","author":"Y Li","year":"2018","unstructured":"Li Y, Zhou H (2018) Moving towards improved vaccines for Toxoplasma gondii. Expert Opin Biol Ther 18(3):273\u2013280. https:\/\/doi.org\/10.1080\/14712598.2018.1413086","journal-title":"Expert Opin Biol Ther"},{"key":"499_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coi.2018.04.011","volume":"53","author":"A Casadevall","year":"2018","unstructured":"Casadevall A (2018) Antibody-based vaccine strategies against intracellular pathogens. Curr Opin Immunol 53:74\u201380. https:\/\/doi.org\/10.1016\/j.coi.2018.04.011","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"499_CR40","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.4049\/jimmunol.164.5.2629","volume":"164","author":"H Kang","year":"2000","unstructured":"Kang H, Remington JS, Suzuki Y (2000) Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. J Immunol 164(5):2629\u20132634. https:\/\/doi.org\/10.4049\/jimmunol.164.5.2629","journal-title":"J Immunol"},{"issue":"3","key":"499_CR41","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1128\/IAI.68.3.1026-1033.2000","volume":"68","author":"PC Sayles","year":"2000","unstructured":"Sayles PC, Gibson GW, Johnson LL (2000) B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun 68(3):1026\u20131033. https:\/\/doi.org\/10.1128\/IAI.68.3.1026-1033.2000","journal-title":"Infect Immun"},{"issue":"41","key":"499_CR42","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1016\/j.vaccine.2018.08.068","volume":"36","author":"M Roozbehani","year":"2018","unstructured":"Roozbehani M, Falak R, Mohammadi M, Hemphill A, Razmjou E, Meamar AR, Masoori L, Khoshmirsafa M, Moradi M, Gharavi MJ (2018) Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection. Vaccine 36(41):6124\u20136132. https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.068","journal-title":"Vaccine"},{"key":"499_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fimmu.2018.00317","volume":"9","author":"Z Lakhrif","year":"2018","unstructured":"Lakhrif Z, Moreau A, Herault B, Di-Tommaso A, Juste M, Moire N, Dimier-Poisson I, Mevelec MN, Aubrey N (2018) Targeted delivery of Toxoplasma gondii antigens to dendritic cells promote immunogenicity and protective efficiency against toxoplasmosis. Front Immunol 9:317. https:\/\/doi.org\/10.3389\/fimmu.2018.00317","journal-title":"Front Immunol"},{"issue":"sup2","key":"499_CR44","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/21691401.2018.1478421","volume":"46","author":"H Naeem","year":"2018","unstructured":"Naeem H, Sana M, Islam S, Khan M, Riaz F, Zafar Z, Akbar H, Shehzad W, Rashid I (2018) Induction of Th1 type-oriented humoral response through intranasal immunization of mice with SAG1-Toxoplasma gondii polymeric nanospheres. Artif Cells Nanomed Biotechnol 46(sup2):1025\u20131034. https:\/\/doi.org\/10.1080\/21691401.2018.1478421","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"11","key":"499_CR45","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1007\/s00436-015-4652-3","volume":"114","author":"Y Xu","year":"2015","unstructured":"Xu Y, Zhang NZ, Wang M, Dong H, Feng SY, Guo HC, Zhu XQ (2015) A long-lasting protective immunity against chronic toxoplasmosis in mice induced by recombinant rhoptry proteins encapsulated in poly (lactide-co-glycolide) microparticles. Parasitol Res 114(11):4195\u20134203. https:\/\/doi.org\/10.1007\/s00436-015-4652-3","journal-title":"Parasitol Res"},{"issue":"4","key":"499_CR46","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.vaccine.2010.11.002","volume":"29","author":"B Dziadek","year":"2011","unstructured":"Dziadek B, Gatkowska J, Brzostek A, Dziadek J, Dzitko K, Grzybowski M, Dlugonska H (2011) Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis. Vaccine 29(4):821\u2013830. https:\/\/doi.org\/10.1016\/j.vaccine.2010.11.002","journal-title":"Vaccine"},{"issue":"1","key":"499_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00430-016-0483-9","volume":"206","author":"I Rashid","year":"2017","unstructured":"Rashid I, Moire N, Heraut B, Dimier-Poisson I, Mevelec MN (2017) Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route. Med Microbiol Immunol 206(1):53\u201362. https:\/\/doi.org\/10.1007\/s00430-016-0483-9","journal-title":"Med Microbiol Immunol"},{"key":"499_CR48","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3389\/fimmu.2020.02183","volume":"11","author":"C Ducournau","year":"2020","unstructured":"Ducournau C, Moire N, Carpentier R, Cantin P, Herkt C, Lantier I, Betbeder D, Dimier-Poisson I (2020) Effective nanoparticle-based nasal vaccine against latent and congenital toxoplasmosis in sheep. Front Immunol 11:2183. https:\/\/doi.org\/10.3389\/fimmu.2020.02183","journal-title":"Front Immunol"},{"issue":"3","key":"499_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.pt.2019.01.005","volume":"35","author":"JL Wang","year":"2019","unstructured":"Wang JL, Zhang NZ, Li TT, He JJ, Elsheikha HM, Zhu XQ (2019) Advances in the development of anti-Toxoplasma gondii vaccines: challenges, opportunities, and perspectives. Trends Parasitol 35(3):239\u2013253. https:\/\/doi.org\/10.1016\/j.pt.2019.01.005","journal-title":"Trends Parasitol"},{"issue":"12","key":"499_CR50","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1021\/acs.molpharmaceut.9b00860","volume":"16","author":"P Gu","year":"2019","unstructured":"Gu P, Wusiman A, Zhang Y, Liu Z, Bo R, Hu Y, Liu J, Wang D (2019) Rational design of PLGA nanoparticle vaccine delivery systems to improve immune responses. Mol Pharm 16(12):5000\u20135012. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00860","journal-title":"Mol Pharm"},{"issue":"2","key":"499_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2020033273","volume":"37","author":"A Garg","year":"2020","unstructured":"Garg A, Dewangan HK (2020) Nanoparticles as adjuvants in vaccine delivery. Crit Rev Ther Drug Carrier Syst 37(2):183\u2013204. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2020033273","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"3","key":"499_CR52","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1080\/21645515.2015.1102804","volume":"12","author":"M Allahyari","year":"2016","unstructured":"Allahyari M, Mohit E (2016) Peptide\/protein vaccine delivery system based on PLGA particles. Hum Vaccin Immunother 12(3):806\u2013828. https:\/\/doi.org\/10.1080\/21645515.2015.1102804","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"499_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10(11):787\u2013796. https:\/\/doi.org\/10.1038\/nri2868","journal-title":"Nat Rev Immunol"},{"key":"499_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111276","volume":"137","author":"A Katebi","year":"2021","unstructured":"Katebi A, Varshochian R, Riazi-Rad F, Ganjalikhani-Hakemi M, Ajdary S (2021) Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation. Biomed Pharmacother 137:111276. https:\/\/doi.org\/10.1016\/j.biopha.2021.111276","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"499_CR55","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120692","volume":"3","author":"EA Thompson","year":"2018","unstructured":"Thompson EA, Ols S, Miura K, Rausch K, Narum DL, Spangberg M, Juraska M, Wille-Reece U, Weiner A, Howard RF et al (2018) TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI Insight 3(10):e120692. https:\/\/doi.org\/10.1172\/jci.insight.120692","journal-title":"JCI Insight"},{"issue":"12","key":"499_CR56","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1586\/erv.11.126","volume":"10","author":"S Jain","year":"2011","unstructured":"Jain S, O\u2019Hagan DT, Singh M (2011) The long-term potential of biodegradable poly (lactideco-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccine 10(12):1731\u20131742","journal-title":"Expert Rev Vaccine"},{"key":"499_CR57","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3389\/fimmu.2019.00707","volume":"10","author":"J Koerner","year":"2019","unstructured":"Koerner J, Horvath D, Groettrup M (2019) Harnessing Dendritic Cells for Poly (D, L-lactide-co-glycolide) Microspheres (PLGA MS)\u2014Mediated Anti-tumor Therapy. Front Immunol 10:707. https:\/\/doi.org\/10.3389\/fimmu.2019.00707","journal-title":"Front Immunol"},{"issue":"3","key":"499_CR58","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ (2011) Poly Lactic-co-Glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers-Basel 3(3):1377\u20131397. https:\/\/doi.org\/10.3390\/polym3031377","journal-title":"Polymers-Basel"},{"issue":"12","key":"499_CR59","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1586\/erv.11.126","volume":"10","author":"S Jain","year":"2011","unstructured":"Jain S, O\u2019Hagan DT, Singh M (2011) The long-term potential of biodegradable poly (lactideco-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines 10(12):1731\u20131742. https:\/\/doi.org\/10.1586\/erv.11.126","journal-title":"Expert Rev Vaccines"},{"issue":"29","key":"499_CR60","doi-asserted-by":"publisher","first-page":"8385","DOI":"10.1016\/j.biomaterials.2014.05.067","volume":"35","author":"Q Wang","year":"2014","unstructured":"Wang Q, Tan MT, Keegan BP, Barry MA, Heffernan MJ (2014) Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation. Biomaterials 35(29):8385\u20138393. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.05.067","journal-title":"Biomaterials"},{"issue":"3","key":"499_CR61","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.addr.2004.09.007","volume":"57","author":"Y Waeckerle-Men","year":"2005","unstructured":"Waeckerle-Men Y, Groettrup M (2005) PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 57(3):475\u2013482. https:\/\/doi.org\/10.1016\/j.addr.2004.09.007","journal-title":"Adv Drug Deliv Rev"},{"issue":"10\u201311","key":"499_CR62","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.addr.2011.05.021","volume":"63","author":"S Hamdy","year":"2011","unstructured":"Hamdy S, Haddadi A, Hung RW, Lavasanifar A (2011) Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 63(10\u201311):943\u2013955. https:\/\/doi.org\/10.1016\/j.addr.2011.05.021","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"499_CR63","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jconrel.2007.09.013","volume":"125","author":"RC Mundargi","year":"2008","unstructured":"Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM (2008) Nano\/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J Control Release 125(3):193\u2013209. https:\/\/doi.org\/10.1016\/j.jconrel.2007.09.013","journal-title":"J Control Release"},{"issue":"1","key":"499_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4155\/tde.14.91","volume":"6","author":"DN Kapoor","year":"2015","unstructured":"Kapoor DN, Bhatia A, Kaur R, Sharma R, Kaur G, Dhawan S (2015) PLGA: a unique polymer for drug delivery. Ther Deliv 6(1):41\u201358. https:\/\/doi.org\/10.4155\/tde.14.91","journal-title":"Ther Deliv"},{"issue":"1","key":"499_CR65","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijpharm.2017.08.118","volume":"532","author":"CR de Azevedo","year":"2017","unstructured":"de Azevedo CR, von Stosch M, Costa MS, Ramos A, Cardoso MM, Danhier F, Pr\u00e9at V, Oliveira R (2017) Modeling of the burst release from PLGA micro-and nanoparticles as function of physicochemical parameters and formulation characteristics. Int J Pharm 532(1):229\u2013240. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.08.118","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"499_CR66","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijpharm.2011.01.045","volume":"408","author":"V Saini","year":"2011","unstructured":"Saini V, Jain V, Sudheesh MS, Jaganathan KS, Murthy PK, Kohli DV (2011) Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen. Int J Pharm 408(1\u20132):50\u201357. https:\/\/doi.org\/10.1016\/j.ijpharm.2011.01.045","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"499_CR67","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijpharm.2015.01.008","volume":"480","author":"C Martin-Sabroso","year":"2015","unstructured":"Martin-Sabroso C, Fraguas-Sanchez AI, Aparicio-Blanco J, Cano-Abad MF, Torres-Suarez AI (2015) Critical attributes of formulation and of elaboration process of PLGA-protein microparticles. Int J Pharm 480(1\u20132):27\u201336. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.01.008","journal-title":"Int J Pharm"},{"issue":"1","key":"499_CR68","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1517\/17425247.2.1.29","volume":"2","author":"LR Brown","year":"2005","unstructured":"Brown LR (2005) Commercial challenges of protein drug delivery. Expert Opin Drug Deliv 2(1):29\u201342. https:\/\/doi.org\/10.1517\/17425247.2.1.29","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"499_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","volume":"75","author":"A Kumari","year":"2010","unstructured":"Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B 75(1):1\u201318. https:\/\/doi.org\/10.1016\/j.colsurfb.2009.09.001","journal-title":"Colloids Surf B"},{"issue":"1","key":"499_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-019-1526-5","volume":"21","author":"J Zhu","year":"2020","unstructured":"Zhu J, Qin F, Ji Z, Fei W, Tan Z, Hu Y, Zheng C (2020) Mannose-modified PLGA nanoparticles for sustained and targeted delivery in hepatitis B virus immunoprophylaxis. AAPS PharmSciTech 21(1):1\u20139. https:\/\/doi.org\/10.1208\/s12249-019-1526-5","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"499_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194620","volume":"13","author":"AS Ashhurst","year":"2018","unstructured":"Ashhurst AS, Parumasivam T, Chan JGY, Lin LC, Fl\u00f3rido M, West NP, Chan H-K, Britton WJ (2018) PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection. PLoS ONE 13(3):e0194620. https:\/\/doi.org\/10.1371\/journal.pone.0194620","journal-title":"PLoS ONE"},{"issue":"1","key":"499_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1756-3305-6-34","volume":"6","author":"SC Chuang","year":"2013","unstructured":"Chuang SC, Ko JC, Chen CP, Du JT, Yang CD (2013) Induction of long-lasting protective immunity against Toxoplasma gondii in BALB\/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles. Parasit Vectors 6(1):34. https:\/\/doi.org\/10.1186\/1756-3305-6-34","journal-title":"Parasit Vectors"},{"key":"499_CR73","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1051\/parasite\/2017004","volume":"24","author":"SC Chuang","year":"2017","unstructured":"Chuang SC, Chung YC, Yang CD (2017) Protective immunity against toxoplasmosis in mice induced by single-dose immunization with rSAG1\/2 protein released from poly(lactide-co-glycolide) microparticles. Parasite 24:5. https:\/\/doi.org\/10.1051\/parasite\/2017004","journal-title":"Parasite"},{"issue":"4","key":"499_CR74","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.exppara.2013.04.002","volume":"134","author":"SC Chuang","year":"2013","unstructured":"Chuang SC, Ko JC, Chen CP, Du JT, Yang CD (2013) Encapsulation of chimeric protein rSAG1\/2 into poly(lactide-co-glycolide) microparticles induces long-term protective immunity against Toxoplasma gondii in mice. Exp Parasitol 134(4):430\u2013437. https:\/\/doi.org\/10.1016\/j.exppara.2013.04.002","journal-title":"Exp Parasitol"},{"issue":"12","key":"499_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0031182014000997","volume":"141","author":"SC Chuang","year":"2014","unstructured":"Chuang SC, Yang CD (2014) Sustained release of recombinant surface antigen 2 (rSAG2) from poly(lactide-co-glycolide) microparticles extends protective cell-mediated immunity against Toxoplasma gondii in mice. Parasitology 141(12):1\u201310. https:\/\/doi.org\/10.1017\/S0031182014000997","journal-title":"Parasitology"},{"key":"499_CR76","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.exppara.2016.09.008","volume":"170","author":"M Allahyari","year":"2016","unstructured":"Allahyari M, Mohabati R, Amiri S, Rastaghi ARE, Babaie J, Mahdavi M, Vatanara A, Golkar M (2016) Synergistic effect of rSAG1 and rGRA2 antigens formulated in PLGA microspheres in eliciting immune protection against Toxoplasama gondii. Experim Para 170:236\u2013246. https:\/\/doi.org\/10.1016\/j.exppara.2016.09.008","journal-title":"Experim Para"},{"key":"499_CR77","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jim.2014.11.012","volume":"416","author":"M Allahyari","year":"2015","unstructured":"Allahyari M, Mohabati R, Babaie J, Amiri S, Siavashani ZJ, Zare M, Sadeghiani G, Golkar M (2015) Production of in-vitro refolded and highly antigenic SAG1 for development of a sensitive and specific Toxoplasma IgG ELISA. J Immunol Methods 416:157\u2013166. https:\/\/doi.org\/10.1016\/j.jim.2014.11.012","journal-title":"J Immunol Methods"},{"issue":"4","key":"499_CR78","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.diagmicrobio.2007.03.003","volume":"58","author":"M Golkar","year":"2007","unstructured":"Golkar M, Rafati S, Abdel-Latif MS, Brenier-Pinchart MP, Fricker-Hidalgo H, Sima BK, Babaie J, Pelloux H, Cesbron-Delauw MF, Mercier C (2007) The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women. Diagn Microbiol Infect Dis 58(4):419\u2013426. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2007.03.003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"499_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101327","volume":"55","author":"M Allahyari","year":"2020","unstructured":"Allahyari M, Mohabati R, Vatanara A, Golkar M (2020) In-vitro and in-vivo comparison of rSAG1-loaded PLGA prepared by encapsulation and adsorption methods as an efficient vaccine against Toxoplasma gondii\u201d. J Drug Deliv Sci Technol 55:101327. https:\/\/doi.org\/10.1016\/j.jddst.2019.101327","journal-title":"J Drug Deliv Sci Technol"},{"issue":"5","key":"499_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1600519","volume":"2","author":"MM Pakulska","year":"2016","unstructured":"Pakulska MM, Elliott Donaghue I, Obermeyer JM, Tuladhar A, McLaughlin CK, Shendruk TN, Shoichet MS (2016) Encapsulation-free controlled release: electrostatic adsorption eliminates the need for protein encapsulation in PLGA nanoparticles. Sci Adv 2(5):e1600519. https:\/\/doi.org\/10.1126\/sciadv.1600519","journal-title":"Sci Adv"},{"issue":"1\u20132","key":"499_CR81","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ijpharm.2011.05.049","volume":"415","author":"S Fredenberg","year":"2011","unstructured":"Fredenberg S, Wahlgren M, Reslow M, Axelsson A (2011) The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems\u2014a review. Int J Pharm 415(1\u20132):34\u201352. https:\/\/doi.org\/10.1016\/j.ijpharm.2011.05.049","journal-title":"Int J Pharm"},{"issue":"1","key":"499_CR82","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12879-016-1496-0","volume":"16","author":"NZ Zhang","year":"2016","unstructured":"Zhang NZ, Xu Y, Wang M, Chen J, Huang SY, Gao Q, Zhu XQ (2016) Vaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactide-co-glycolide) microspheres induces long-term protective immunity in mice. BMC Infect Dis 16(1):168. https:\/\/doi.org\/10.1186\/s12879-016-1496-0","journal-title":"BMC Infect Dis"},{"issue":"2","key":"499_CR83","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5455\/javar.2019.f329","volume":"6","author":"K Hajissa","year":"2019","unstructured":"Hajissa K, Zakaria R, Suppian R, Mohamed Z (2019) Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: a mini-review. J Adv Vet Anim Res 6(2):174. https:\/\/doi.org\/10.5455\/javar.2019.f329","journal-title":"J Adv Vet Anim Res"},{"key":"499_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.726615","volume":"12","author":"Z Yu","year":"2021","unstructured":"Yu Z, Cao W, Gao X, Aleem MT, Liu J, Luo J, Yan R, Xu L, Song X, Li X (2021) With Chitosan and PLGA as the delivery vehicle, Toxoplasma gondii oxidoreductase-based DNA vaccines decrease parasite burdens in Mice. Front Immunol 12:726615. https:\/\/doi.org\/10.3389\/fimmu.2021.726615","journal-title":"Front Immunol"},{"issue":"10","key":"499_CR85","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/pharmaceutics13101582","volume":"13","author":"Z Yu","year":"2021","unstructured":"Yu Z, Lu Y, Cao W, Aleem MT, Liu J, Luo J, Yan R, Xu L, Song X, Li X (2021) Nano DNA vaccine encoding Toxoplasma gondii histone deacetylase SIR2 enhanced protective immunity in Mice. Pharmaceutics 13(10):1582. https:\/\/doi.org\/10.3390\/pharmaceutics13101582","journal-title":"Pharmaceutics"},{"key":"499_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s11686-021-00415-2","author":"L Wu","year":"2021","unstructured":"Wu L, Yang H, Wang J, Yu X, He Y, Chen S (2021) A novel combined DNA vaccine encoding Toxoplasma gondii SAG1 and ROP18 provokes protective immunity against a lethal challenge in Mice. Acta Parasitol. https:\/\/doi.org\/10.1007\/s11686-021-00415-2","journal-title":"Acta Parasitol"}],"container-title":["Acta Parasitologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-021-00499-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11686-021-00499-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-021-00499-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T16:27:17Z","timestamp":1653323237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11686-021-00499-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["499"],"URL":"https:\/\/doi.org\/10.1007\/s11686-021-00499-w","relation":{},"ISSN":["1230-2821","1896-1851"],"issn-type":[{"value":"1230-2821","type":"print"},{"value":"1896-1851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"2 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author has no conflict of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}